Aripiprazole Augmentation in the Treatment of Military-Related PTSD with Major Depression: a retrospective chart review
2011

Aripiprazole for Treating PTSD and Depression in Veterans

Sample size: 27 publication Evidence: moderate

Author Information

Author(s): Richardson J Don, Fikretoglu Deniz, Liu Aihua, McIntosh Diane

Primary Institution: St. Joseph's Health Care London - Parkwood Hospital

Hypothesis

Aripiprazole would be efficacious for treatment-resistant military-related PTSD with comorbid major depression.

Conclusion

The addition of aripiprazole contributed to a reduction in both PTSD and depression symptoms in veterans.

Supporting Evidence

  • PTSD severity decreased from 56.11 at baseline to 46.85 at 12 weeks.
  • Depression severity decreased from 30.44 at baseline to 20.67 at 12 weeks.
  • 37% of participants were considered responders for PTSD symptoms.
  • 19% of participants were considered responders for depression symptoms.

Takeaway

This study looked at veterans with PTSD and depression and found that adding a medication called aripiprazole helped reduce their symptoms.

Methodology

A retrospective chart review of patients who received a 12-week course of adjunctive aripiprazole.

Limitations

Small sample size, retrospective design, and lack of a control group.

Participant Demographics

Most participants were men (96.3%) with an average age of 39.36 years.

Statistical Information

P-Value

<0.0001

Statistical Significance

p<0.0001

Digital Object Identifier (DOI)

10.1186/1471-244X-11-86

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication